OncoMatch/Clinical Trials/NCT07019220

Chemoablation for Low-Grade Bladder Cancer

Is NCT07019220 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Gemcitabine for bladder (urothelial, transitional cell) cancer.

Phase 2RecruitingEkaterina LaukhtinaNCT07019220Data as of Jun 2026Location: Austria

Treatment: Gemcitabine — The goal of this single arm, prospective, open-label, investigator-initiated Phase 2 clinical trial is to evaluate the efficacy of intravesical chemoablation in patients with low grade bladder cancer.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

Gemcitabine

Disease stage

Grade: low (eau risk)

Prior therapy

Cannot have received: intravesical therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07019220 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior intravesical therapy disqualifies patients from enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify